期刊文献+

新型4-取代苯胺喹唑啉衍生物的合成与抗肿瘤活性研究 被引量:5

Study on Synthesis and Antitumor Activities of Novel 4-Substituted Anilinoquinazoline Derivatives
下载PDF
导出
摘要 以6-碘喹唑啉-4-酮为原料,经氯代、胺化、Suzuki偶联、Wittig-horner等反应合成了7个新型的4-取代苯胺喹唑啉衍生物(5a^5g),其结构经1H NMR和HR-MS(ESI)表征。采用MTT法研究了5a^5g对人乳腺癌细胞(MCF-7)、人肺癌细胞(A549)和人皮肤鳞癌细胞(A431)的抑制活性。结果表明:5a^5g对肿瘤细胞均具有明显的抑制活性;其中5e的抑制活性(IC50=0.13~5.26μmol·L-1)优于拉帕替尼(IC50=0.21~15.56μmol·L-1)。 Seven novel 4-substituted anilinoquinazoline derivatives( 5 a ~ 5 g) were synthesized from 6-iodoquinazolin-4-one by chlorination,amination,Suzuki coupling and Wittig-Horner reaction. The structures were characterized by1 H NMR and HR-MS( ESI). The in vitro antitumor activities of 5 a ~5 g against human cancer cells A-549,MCF-7 and A431 were investigated by MTT method. The results indicated that 5 a ~ 5 g showed good inhibition activities and 5 e showed better inhibition activities( IC50= 0. 13 ~ 5. 26 μmol·L~(-1)) than Lapatinib( IC50= 0. 21 ~ 15. 56 μmol·L~(-1)).
作者 金正盛 蔡志强 方舒慧 赵蓉 丁海关 曹慧 许娣 孟苗苗 李英杰 马启朋 JIN Zheng-sheng;CAI Zhi-qiang;FANG Shu-hui;ZHAO Rong;DING Hai-guan;CAO Hui;XU Di;MENG Miao-miao;LI Ying-jie;MA Qi-peng(School of Petrochemical Engineering,Shenyang University of Technolog,Liaoyang 111003,China;Key Laboratory for Chemical Drug Research of Shandong Province,Institute of Phamaceutical Sciences of Shandong Province,Jinan 250101,China;Petrochina,Fushun Petrochemical Company,Fushun 113008,China)
出处 《合成化学》 CAS CSCD 北大核心 2018年第6期389-393,399,共6页 Chinese Journal of Synthetic Chemistry
基金 辽宁省教育厅科学研究项目(L2015383) 博士科研启动基金(521422) 沈阳市科技计划项目(18-004-4-32)
关键词 6-碘喹唑啉-4-酮 拉帕替尼 喹唑啉 合成 抗肿瘤活性 6-iodoquinazolin-4-one Lapatinib quinazoline synthesis antitumor activity
  • 相关文献

参考文献5

二级参考文献49

  • 1吕会增,魏波,陈图峰,苏雁甜,叶小勇,陈新岐,卫洪波.奥沙利铂对人结肠癌细胞LoVo和SW480/M5作用的实验研究[J].消化肿瘤杂志(电子版),2012,4(1):34-39. 被引量:2
  • 2赖宜天,张喜全,郭键,李宝林.白藜芦醇类似物的合成研究[J].化学试剂,2007,29(5):257-259. 被引量:10
  • 3Yang S, Li Z, Jin L H, et al. Synthesis and bioactivity of 4-alkyl (aryl) thioquinazoline derivatives [ J] Bioorg Med Chem Lett, 2007,17(8) :2193 -2196.
  • 4Corbett J W, Pan S L, Markwalder J A,et al. 3,3a-Dihydropyrano [4,3,2-de ] quinazolin-2 (1H) -ones are potent non-nucleoside reverse transcriptase inhibitors [ J ]. Bioorg Med Chem Lett,2001, 11:211 -214.
  • 5Chandrika P M,Yakaiah T, Rao A R R, et al. Synthesis of novel 4, 6-disubstituted quinazoline derivatives,their anti-inflammatory and anti-cancer activity (cytotoxic) against U937 leukemia cell lines [ J]. Eur J Med Chem,2008,43 (4) : 846 - 852.
  • 6Ranson M, Hammond L A, Ferry D ,et al. ZD1839, a selective oral epidermal growth factor reeeptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I triM[ J ]. J Clin 0ncol,2002,20:2240 -2250.
  • 7Ciardiello F,Tortora G. A novel approach in the treatment of cancer:targeting the epidermal growth factor receptor [ J]. Clin Cancer Res,2001,7 :2958 - 2970.
  • 8Wenle X,Mullin R J,Keith B R,et al. Anti-tumor activity of GW - 572016 :a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erkl/2 and AKT pathways [ J ]. Oncogene,2002,21 : 6255 - 6263.
  • 9Grtinwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment[ J]. J Nat Cancer Ins, 2003,95(12) :851 -867.
  • 10Cha M Y,Lee K O,Kim J W,et al. Discovery of a novel Her - 1/ Her -2 dual tyrosine kinase inhibitor for the treatment of Her - 1 selective inhibitor-resistant non-small cell lung cancer [ J ]. J Med Chem ,2009,52:6880 - 6888.

共引文献20

同被引文献24

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部